Biohacking PR: How Performance Brands Escape the Hype Trap With Earned Media

Here's a number that should reshape every biohacking brand's marketing budget: earned media drives 84% of all AI citations—journalism, academic research and credible third-party content—according to Muck Rack's Generative Pulse analysis of more than 25 million links cited by ChatGPT, Claude and Gemini. Paid and advertorial content? 0.3%.

Credibility is no longer just a matter of human trust. It's a data signal shaping how algorithms describe your company, your competitors and your category. When a buyer asks an AI tool who leads performance wellness, the answer is assembled from coverage that others deemed credible enough to cite. As PRSA's Jennifer Regen Bisbee put it, "third-party validation is now the premium currency of credibility."

That matters doubly in biohacking—a category where rigorous science and reckless claims share shelf space, and where Grand View Research values the market at $24.8 billion, heading toward $69 billion by 2030. As the category expands, so does the need to separate credible innovation from commercial noise. Earned media should be built into biohacking brand strategy from the start, not bolted on after launch.

From Fringe to Mainstream—and Into the Credibility Gap

"Biohacking" used to mean DIY scientists and spreadsheet-tracking early adopters. Today it spans wearables, diagnostics, personalized nutrition, recovery tools, longevity clinics and performance technologies. Yet the word still splits the room: innovation and empowerment to some, pseudoscience in sleek packaging to others.

That perception gap is the marketing challenge. Performance brands must be bold enough to stand out and credible enough to stand up to scrutiny. Paid and owned channels can tell your story. Only earned media can prove it deserves to be told.

Why Owned and Paid Media Can't Carry the Load

Owned media is your voice. Paid media is your megaphone. Both are useful, and both are controlled by you, which is precisely the problem in a scrutinized category. A sleek website can call a platform "innovative." A sponsored article can flaunt impressive data. Everyone knows who wrote the script.

Earned media adds the one thing you can't buy: an independent filter. Journalists test claims, editors add context, and sometimes limitations get exposed. That friction is the value—it's the difference between saying you're credible and proving it.

How Earned Media Changes the Credibility Equation

There's a big difference between a company calling itself a category leader and a respected trade publication calling to ask for its take. That credibility transfer sits at the heart of biohacking PR. Communications strategist Gini Dietrich argues that strong earned media can "validate your expertise" and "transfer trust"—and in a market she describes as full of "AI slop, made-up expertise, and confidence masquerading as competence," that transfer is worth more than ever.

The proof is testable. In 2024, biomarker platform InsideTracker published a peer-reviewed analysis in PLOS Digital Health covering five years of data from more than 20,000 users, showing statistically significant improvements across 43 biomarkers—including HbA1c reductions among elevated-risk users. That scale gave journalists something real to examine, and many did. The resulting coverage carried weight precisely because the evidence had been through the wringer. Clear, verifiable evidence gives journalists something credible to test; scrutiny gives the coverage its authority.

Earned Media Becomes a Reusable Business Asset

Modern B2B buyers do the bulk of their research before they ever talk to you—Gartner finds buyers spend just 17% of their journey with suppliers. The rest is independent research, where they compare claims, review leadership and look for evidence a partner understands both science and risk. Your media footprint shapes that invisible evaluation.

Coverage in a respected trade outlet gives sales teams an independent story to share. Repeated expert commentary positions executives as credible sources. A strong feature helps internal champions sell you to legal, procurement and finance. For ingredient suppliers, wearable developers, contract manufacturers and technology platforms—businesses selling confidence as much as capability—each placement compounds into a portfolio of third-party validation that shortens the path from curiosity to contract.

Scrutiny Is Part of the Value

Brands sometimes treat earned media like free advertising, and miss the point entirely. Its power lies in the questions: journalists ask for data, consult outside experts and challenge inflated language. For hype-driven companies, that stings. For evidence-driven ones, it's protection—every skeptical question your claims survive becomes credibility your competitors can't fake.

The companies that win in biohacking won't chase buzz. They'll prove their work and let others tell the story.

‍

FAQ Biohacking PR

What is biohacking PR?

Biohacking PR is earned-media strategy for performance wellness brands—wearables, diagnostics, supplements, recovery technology and the B2B companies serving them. It builds credibility through journalism, expert commentary and thought leadership in a category where audiences and algorithms are skeptical of self-authored claims.

Why does earned media matter more for biohacking brands than paid?

Because the category's core challenge is trust, not awareness. Earned coverage carries independent editorial judgment, and it drives the overwhelming majority of citations in AI search tools, where paid content is nearly invisible.

When should a biohacking brand start PR?

Before launch-stage claims harden into marketing copy. Early messaging discipline—knowing what your evidence supports and where your claims stop—determines whether media scrutiny becomes validation or a liability.

Grasslands helps performance and biohacking brands earn attention without losing credibility. Explore our Longevity & Wellness PR + Marketing practice or read our longevity marketing pillar guide.